EU/3/10/756: Orphan designation for the prevention of scarring post glaucoma filtration surgery

Tranilast

Table of contents

Overview

On 27 July 2010, orphan designation (EU/3/10/756) was granted by the European Commission to Altacor Ltd, United Kingdom, for tranilast for the prevention of scarring post glaucoma filtration surgery.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France in November 2019.

In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.

Key facts

Active substance
Tranilast
Intended use
Prevention of scarring post glaucoma filtration surgery
Orphan designation status
Positive
EU designation number
EU/3/10/756
Date of designation
27/07/2010
Sponsor

Voisin Consulting Life Sciences 
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
France
Tel. +33 1413 18300
E-mail: orphan@voisinconsulting.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating